Preparation and characterization of solid dispersion using a novel amphiphilic copolymer to enhance dissolution and oral bioavailability of sorafenib

Powder Technology

Volumn 283, Issue , 2015, Pages 260-265

  Truong, Duy Hieu ^a   Tran, Tuan Hiep ^a   Ramasamy, Thiruganesh ^a   Choi, Ju Yeon ^a   Choi, Han Gon ^b   Yong, Chul Soon ^a   Kim, Jong Oh ^a  

^a Yeungnam University   (South Korea)

^b Hanyang University   (South Korea)

Author keywords

Dissolution; Solid dispersion; Solubilization; Soluplus; Sorafenib

Indexed keywords

BIOCHEMISTRY; COPOLYMERS; DIFFERENTIAL SCANNING CALORIMETRY; DISPERSIONS; POLYVINYL ACETATES; SODIUM SULFATE; X RAY DIFFRACTION;

AMPHIPHILIC CO-POLYMERS; ORAL BIOAVAILABILITIES; POORLY WATER-SOLUBLE DRUGS; POWDER X RAY DIFFRACTION; SOLID DISPERSION; SOLUBILIZATION; SOLUPLUS; SORAFENIB;

DISSOLUTION;

AMPHOPHILE; COPOLYMER; DODECYL SULFATE SODIUM; POLYVINYL CAPROLACTAM POLYVINYL ACETATE POLYETHYLENEGLYCOL GRAFT COPOLYMER; SORAFENIB; UNCLASSIFIED DRUG; WATER;

ANIMAL EXPERIMENT; AQUEOUS SOLUTION; AREA UNDER THE CURVE; ARTICLE; CRYSTALLIZATION; DIFFERENTIAL SCANNING CALORIMETRY; DISPERSION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SOLUBILITY; DRUG SYNTHESIS; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PH MEASUREMENT; PHYSICAL CHEMISTRY; POWDER; PROCESS OPTIMIZATION; RAT; SOLID DISPERSION; SPRAY DRYING; SURFACE PROPERTY; TIME TO MAXIMUM PLASMA CONCENTRATION; X RAY POWDER DIFFRACTION;

EID: 84930625148     PISSN: 00325910     EISSN: 1873328X     Source Type: Journal    
DOI: 10.1016/j.powtec.2015.04.044     Document Type: Article

References (34)

1. Wilhelm S.M., Carter C., Tang L., Wilkie D., McNabola A., Rong H., Chen C., Zhang X., Vincent P., McHugh M. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004, 64:7099-7109.
2. Liu L., Cao Y., Chen C., Zhang X., McNabola A., Wilkie D., Wilhelm S., Lynch M., Carter C. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res. 2006, 66:11851-11858.
3. Kane R.C., Farrell A.T., Madabushi R., Booth B., Chattopadhyay S., Sridhara R., Justice R., Pazdur R. Sorafenib for the treatment of unresectable hepatocellular carcinoma. Oncologist 2009, 14:95-100.
4. US Food and Drug Administration, FDA Approval for Sorafenib Tosylate, Updated: 2013-11-26 Available from URL:. http://www.cancer.gov/cancertopics/druginfo/fda-sorafenib-tosylate.
5. Wang X.-Q., Fan J.-M., Liu Y.-O., Zhao B., Jia Z.-R., Zhang Q. Bioavailability and pharmacokinetics of sorafenib suspension, nanoparticles and nanomatrix for oral administration to rat. Int. J. Pharm. 2011, 419:339-346.
6. Zhang Z., Niu B., Chen J., He X., Bao X., Zhu J., Yu H., Li Y. The use of lipid-coated nanodiamond to improve bioavailability and efficacy of sorafenib in resisting metastasis of gastric cancer. Biomaterials 2014, 35:4565-4572.
7. Ha E.S., Baek I.H., Cho W., Hwang S.J., Kim M.S. Preparation and evaluation of solid dispersion of atorvastatin calcium with Soluplus by spray drying technique. Chem. Pharm. Bull. 2014, 62:545-551.
8. PCT (International application published under the patent cooperation treaty). Nanoparticulate sorafenib formulations. International publication number WO 2008/008733 A2, 2008.
9. Blanchet B., Billemont B., Cramard J., Benichou A., Chhun S., Harcouet L., Ropert S., Dauphin A., Goldwasser F., Tod M. Validation of an HPLC-UV method for sorafenib determination in human plasma and application to cancer patients in routine clinical practice. J. Pharm. Biomed. Anal. 2009, 49:1109-1114.
10. Strumberg D., Richly H., Hilger R.A., Schleucher N., Korfee S., Tewes M., Faghih M., Brendel E., Voliotis D., Haase C.G. Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J. Clin. Oncol. 2005, 23:965-972.
11. Park Y.-J., Kwon R., Quan Q.Z., Oh D.H., Kim J.O., Hwang M.R., Koo Y.B., Woo J.S., Yong C.S., Choi H.-G. Development of novel ibuprofen-loaded solid dispersion with improved bioavailability using aqueous solution. Arch. Pharm. Res. 2009, 32:767-772.
12. Lim H.-T., Balakrishnan P., Oh D.H., Joe K.H., Kim Y.R., Hwang D.H., Lee Y.-B., Yong C.S., Choi H.-G. Development of novel sibutramine base-loaded solid dispersion with gelatin and HPMC: physicochemical characterization and pharmacokinetics in beagle dogs. Int. J. Pharm. 2010, 397:225-230.
13. Onoue S., Kojo Y., Suzuki H., Yuminoki K., Kou K., Kawabata Y., Yamauchi Y., Hashimoto N., Yamada S. Development of novel solid dispersion of tranilast using amphiphilic block copolymer for improved oral bioavailability. Int. J. Pharm. 2013, 452:220-226.
14. Frizon F., Eloy J.d.O., Donaduzzi C.M., Mitsui M.L., Marchetti J.M. Dissolution rate enhancement of loratadine in polyvinylpyrrolidone K-30 solid dispersions by solvent methods. Powder Technol. 2013, 235:532-539.
15. Konno H., Handa T., Alonzo D.E., Taylor L.S. Effect of polymer type on the dissolution profile of amorphous solid dispersions containing felodipine. Eur. J. Pharm. Biopharm. 2008, 70:493-499.
16. Jung J.-Y., Yoo S.D., Lee S.-H., Kim K.-H., Yoon D.-S., Lee K.-H. Enhanced solubility and dissolution rate of itraconazole by a solid dispersion technique. Int. J. Pharm. 1999, 187:209-218.
17. Yamashita K., Nakate T., Okimoto K., Ohike A., Tokunaga Y., Ibuki R., Higaki K., Kimura T. Establishment of new preparation method for solid dispersion formulation of tacrolimus. Int. J. Pharm. 2003, 267:79-91.
18. Marasini N., Tran T.H., Poudel B.K., Cho H.J., Choi Y.K., Chi S.C., Choi H.G., Yong C.S., Kim J.O. Fabrication and evaluation of pH-modulated solid dispersion for telmisartan by spray-drying technique. Int. J. Pharm. 2013, 441:424-432.
19. Hussain M.D., Saxena V., Brausch J.F., Talukder R.M. Ibuprofen-phospholipid solid dispersions: improved dissolution and gastric tolerance. Int. J. Pharm. 2012, 290-294.
20. Okonogi S., Oguchi T., Yonemochi E., Puttipipatkhachorn S., Yamamoto K. Improved dissolution of ofloxacin via solid dispersion. Int. J. Pharm. 1997, 156:175-180.
21. Mehanna M.M., Motawaa A.M., Samaha M.W. In sight into tadalafil-block copolymer binary solid dispersion: mechanistic investigation of dissolution enhancement. Int. J. Pharm. 2010, 402:78-88.
22. Corrigan O.I. Mechanisms of dissolution of fast release solid dispersions. Drug Dev. Ind. Pharm. 1985, 11:697-724.
23. Paudel A., Worku Z.A., Meeus J., Guns S., Van den Mooter G. Manufacturing of solid dispersions of poorly water soluble drugs by spray drying: formulation and process considerations. Int. J. Pharm. 2013, 453:253-284.
24. Shamma R.N., Basha M. Soluplus®: a novel polymeric solubilizer for optimization of Carvedilol solid dispersions: formulation design and effect of method of preparation. Powder Technol. 2013, 406-414.
25. Thakral N.K., Ray A.R., Bar-Shalom D., Eriksson A.H., Majumdar D.K. Soluplus-solubilized citrated camptothecin-a potential drug delivery strategy in colon cancer. AAPS PharmSciTech 2012, 13:59-66.
26. Linn M., Collnot E.-M., Djuric D., Hempel K., Fabian E., Kolter K., Lehr C.-M. Soluplus® as an effective absorption enhancer of poorly soluble drugs in vitro and in vivo. Eur. J. Pharm. Sci. 2012, 45:336-343.
27. Park Y.-J., Ryu D.-S., Li D.X., Quan Q.Z., Oh D.H., Kim J.O., Seo Y.G., Lee Y.-I., Yong C.S., Woo J.S. Physicochemical characterization of tacrolimus-loaded solid dispersion with sodium carboxylmethyl cellulose and sodium lauryl sulfate. Arch. Pharm. Res. 2009, 32:893-898.
28. Tran T.H., Poudel B.K., Marasini N., Chi S.-C., Choi H.-G., Yong C.S., Kim J.O. Preparation and evaluation of raloxifene-loaded solid dispersion nanoparticle by spray-drying technique without an organic solvent. Int. J. Pharm. 2013, 443:50-57.
29. Joe J.H., Lee W.M., Park Y.J., Joe K.H., Oh D.H., Seo Y.G., Woo J.S., Yong C.S., Choi H.G. Effect of the solid-dispersion method on the solubility and crystalline property of tacrolimus. Int. J. Pharm. 2010, 161-166.
30. Society of Toxicology (SOT), Guiding Principles in the Use of Animals in Toxicology Available from URL:. http://www.toxicology.org/AI/FA/guidingprinciples.pdf.
31. Zhang H., Zhang F.-M., Yan S.-J. Preparation, in vitro release, and pharmacokinetics in rabbits of lyophilized injection of sorafenib solid lipid nanoparticles. Int. J. Nanomedicine 2012, 7:2901-2910.
32. Van Eerdenbrugh B., Taylor L.S. An ab initio polymer selection methodology to prevent crystallization in amorphous solid dispersions by application of crystal engineering principles. CrystEngComm 2011, 13:6171-6178.
33. Kim M. Soluplus-coated colloidal silica nanomatrix system for enhanced supersaturation and oral absorption of poorly water-soluble drugs. Artif. Cells Nanomed. Biotechnol. 2013, 41:363-367.
34. Shoukri R.A., Ahmed I.S., Shamma R.N. In vitro and in vivo evaluation of nimesulide lyophilized orally disintegrating tablets. Eur. J. Pharm. Biopharm. 2009, 73:162-171.